Image

Development of utrophin modulators for the treatment of Duchenne Muscular Dystrophy

Image

Developing small molecules for the treatment of age-related diseases

Image

New agents for tumour detection and therapy

Image

Development of anti-inflammatory agents

Welcome to the Russell Group webpages. The Russell Group is based in the Department of Chemistry and the Department of Pharmacology at the University of Oxford. Explore our website to learn more about our group, collaborative research programmes and publications.

Latest news
Stacks Image 283
Ria at the 64th Biophysical Society Annual Meeting
Ria Dinsdale was awarded a Biophysical Society Award to present at the Annual Meeting in February this year. Read more…
Stacks Image 306
New publication in Angewandte Chemie
Research from the Russell group reveals the Arylhydrocarbon Receptor as the molecular target of the utrophin modulator ezutromid. Read more…
Stacks Image 309
Oxford Times/Mail profile: Angela Russell
Read the article in the Oxford Times profiling Angela Russell - how she began her career in medicinal chemistry and the ground-breaking regenerative medicine approach that OxStem is currently leading. Read more….
Publication highlights
This paper describes the first identification and validation of a disease-modifying target for Duchenne muscular dystrophy (DMD), through target deconvolution of the clinical compound ezutromid. This is a real breakthrough in the field as there is currently no cure for DMD and this work enables the first target‐based drug discovery program in DMD.
Image